Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

terminated133%
not_yet_recruiting133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
unknown

Expanded Access to Gallium Maltolate (GaM)

NCT06404034
not_yet_recruitingphase_1

Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor

NCT07331064
terminatedphase_1

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

NCT00050687

Clinical Trials (3)

Showing 3 of 3 trials
NCT06404034

Expanded Access to Gallium Maltolate (GaM)

Unknown
NCT07331064Phase 1

Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor

Not Yet Recruiting
NCT00050687Phase 1

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3